VIDEO: Menin inhibitors a 'promising new class' of targeted therapy for AML
Click Here to Manage Email Alerts
In this video, Eunice Wang, MD, discusses data presented at the ASH Annual Meeting and Exposition that validates menin inhibitors as a new class of targeted therapy for AML.
"We saw the expansion and further validation of menin inhibitors as a potentially novel and highly promising new class of targeted therapy for patients with acute myeloid leukemia characterized by KMG2A rearrangements or NMP1 mutations," Wang, said, noting a late-breaking phase 2 study that showed meaningful overall response rates for patients with relapsed/refractory KMT2A rearranged acute leukemia who received revumenib monotherapy.
“Clearly the menin inhibitors are moving forward,” Wang, associate professor of oncology, medicine, at Roswell Park Cancer Institute, said.
Reference:
- Jabbour E, et al. A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
- Aldoss I, et al. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Click Here to Manage Email Alerts